Dr Secord On Mirvetuximab Soravtansine In Platinum Sensitive Frα High Ovarian Cancer

Mirvetuximab Soravtansine In Patients With Platinum Resistant Ovarian Angeles a. secord, md, mhsc, professor, obstetrics and gynecology, duke cancer institute, discusses findings from the phase 2 piccolo trial (nct05041257) investigating mirvetuximab. Dr secord noted the need for new treatments in this area, as current therapies for platinum sensitive ovarian cancer lose effectiveness over time. the fda recently fully approved mirvetuximab soravtansine for frα positive, platinum resistant ovarian, fallopian tube, or primary peritoneal cancer, based on the phase 3 mirasol trial, which.

Elahere Mirvetuximab Soravtansine Meets Primary End Point Of Piccolo Angeles a. secord, md, mhsc, professor, obstetrics and gynecology, duke cancer institute, discusses findings from the phase 2 piccolo trial (nct05041257) inv. Secord: piccolo is a phase 2 global, open label, single arm, study of mirvetuximab soravtansine in individuals with heavily pretreated platinum sensitive ovarian cancer. the key. Mirv demonstrated clinically meaningful antitumor activity and favorable tolerability in patients with frα high psoc. the efficacy and safety data support the use of mirv in psoc patients with ≥ 2 prior platinum containing regimens or platinum allergy. clinical trial: nct05041257. Overall, the piccolo trial results suggest that mirvetuximb soravtansine is a promising treatment option for patients with recurrent platinum sensitive ovarian cancer who have high levels of frα expression. here, angeles alvarez secord, md, mhsc, gynecologic oncologist at duke cancer center, discusses the key takeaways from the study presented.

Mirvetuximab Soravtansine In Patients With Platinum Resistant Ovarian Mirv demonstrated clinically meaningful antitumor activity and favorable tolerability in patients with frα high psoc. the efficacy and safety data support the use of mirv in psoc patients with ≥ 2 prior platinum containing regimens or platinum allergy. clinical trial: nct05041257. Overall, the piccolo trial results suggest that mirvetuximb soravtansine is a promising treatment option for patients with recurrent platinum sensitive ovarian cancer who have high levels of frα expression. here, angeles alvarez secord, md, mhsc, gynecologic oncologist at duke cancer center, discusses the key takeaways from the study presented. Among participants with platinum resistant, frα positive ovarian cancer, treatment with mirv showed a significant benefit over chemotherapy with respect to progression free and overall survival and objective response. Listen to a new journal club with lead author dr. angeles alvarez secord and moderator dr. robert coleman as they discuss details on the recently published article the efficacy and safety of mirvetuximab soravtansine in frα positive, third line and later, recurrent platinum sensitive ovarian cancer: the single arm phase 2 piccolo trial. Annals of oncology shared a recent article by a. alvarez secord on x: “new article in press: the efficacy and safety of mirvetuximab soravtansine in frα positive, third line and later, recurrent platinum sensitive ovarian cancer: the single arm phase 2 piccolo trial.”.